Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Response to High Dose Cytarabine (HIDAC) As First Salvage for Relapsed Acute Lymphocytic Leukemia in Patients Receiving HIDAC As Initial Therapy

Anjali S. Advani, MD, Holly Gundacker, Nolyn Nyatanga, MD, Paul Elson, Peter J. Rosen, MD, Jennifer Bates, BS, CCRP, Mikkael A. Sekeres, MD, MS, Matt Kalaycio, MD, Ronald Sobecks, MD, Edward Copelan, MD, Frederick R. Appelbaum, MD

Blood (2011) 118 (21): 2594.

https://doi.org/10.1182/blood.V118.21.2594.2594

Published: 2011

Journal Articles

Absolute Lymphocyte Count At Day 28 Independently Predicts Event-Free and Overall Survival in Adults with Newly Diagnosed Acute Lymphocytic Leukemia

Di Sun, Paul Elson, Michaela Liedtke, MD, Bruno C. Medeiros, MD, Marc Earl, PharmD, RPh, Ash A Alizadeh, MD/PhD, Jennifer Bates, BS, CCRP, Mikkael A. Sekeres, MD, MS, Steven E. Coutre, MD, Matt Kalaycio, MD, Ronald Sobecks, MD, Edward Copelan, MD, Anjali S. Advani, MD

Blood (2011) 118 (21): 2552.

https://doi.org/10.1182/blood.V118.21.2552.2552

Published: 2011

Journal Articles

Lenalidomide and Rituximab Following Autologous Stem Cell Transplantation for B-Cell Non-Hodgkin Lymphoma Is Associated with Unacceptable Myelotoxicity

Robert Dean, MD, Brad Pohlman, MD, Lisa Rybicki, MS, Amanda L. Maggiotto, BS, CCRP, Jennifer Bates, BS, CCRP, Stephen D. Smith, MD, Brian J. Bolwell, MD, John Sweetenham, MD

Blood (2011) 118 (21): 1621.

https://doi.org/10.1182/blood.V118.21.1621.1621

Published: 2011

Journal Articles

Expression of Phosphorylated Signal Transducer and Activator of Transcription 5 (pSTAT5) Is Associated with An Increased Risk of Death In Acute Myeloid Leukemia.

Anna Brady, MD, Sarah Gibson, MD, Lisa Rybicki, MS, Eric Hsi, MD, Edward Copelan, MD, Matt Kalaycio, MD, Mikkael A. Sekeres, MD, MS, Ronald Sobecks, MD, Yogen Saunthararajah, MD, Jennifer Bates, Anjali S. Advani, MD

Blood (2010) 116 (21): 1675.

https://doi.org/10.1182/blood.V116.21.1675.1675

Published: 2010

Journal Articles

A Phase 1 Trial of Imatinib Mesylate with Daunorubicin and Cytarabine for Patients with C-Kit Positive Relapsed AML.

Anjali Advani, MD, Edward A. Copelan, MD, Ronald Sobecks, MD, Mikkael A Sekeres, MD, MS, Jennifer Bates, Mary Lynn Rush, Barbara Tripp, Elysa Noon, PhD, Matthew Howard, MD, Tao Jin, Eric Hsi, MD, Matt Kalaycio, MD

Blood (2008) 112 (11): 955.

https://doi.org/10.1182/blood.V112.11.955.955

Published: 2008

Journal Articles

A Phase 1 Trial of Imatinib Mesylate in Combination with Daunorubicin and Cytarabine for Patients for C-kit Positive Relapsed Acute Myeloid Leukemia (AML).

Anjali S. Advani, MD, Ronald Sobecks, MD, Mikkael A. Sekeres, MD, Ed Copelan, MD, Jennifer Bates, Barbara Tripp, RN, August Salvado, MD, Matt Kalaycio, MD

Blood (2007) 110 (11): 906.

https://doi.org/10.1182/blood.V110.11.906.906

Published: 2007

Journal Articles

Comparison of T Cell (CD3+) Chimerism after Myeloablative (MY) and Nonmyeloablative (NM) Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT).

Ronald Sobecks, MD, Karl Theil, MD, Lisa Rybicki, MS, Jennifer Bates, BS, Matt Kalaycio, MD, Steven Andresen, DO, Brad Pohlman, MD, Robert M. Dean, MD, John William Sweetenham, MD, Laura Bernhard, RN, Kelly Cherni, RN, Mary Serafin, RN, Karen Sands, RN, Jennifer Kosar, RN, Brian J. Bolwell, MD

Blood (2006) 108 (11): 2960.

https://doi.org/10.1182/blood.V108.11.2960.2960

Published: 2006

Journal Articles

Influence of Killer Immunoglobulin-Like Receptor (KIR) Matching on Achieving T Cell (CD3+) Complete Donor Chimerism (CDC) in Related Donor Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NMHSCT).

Ronald Sobecks, MD, Edward J. Ball, PhD, Medhat Askar, MD, PhD., Karl Theil, MD, Lisa Rybicki, MS, Dawn Thomas, CHS, Jennifer Bates, BS, Matt Kalaycio, MD, Steven Andresen, DO, Brad Pohlman, MD, Robert M. Dean, MD, John William Sweetenham, MD, Laura Bernhard, RN, Kelly Cherni, RN, Jaroslaw P. Maciejewski, MD, MS, Brian J. Bolwell, MD

Blood (2006) 108 (11): 3012.

https://doi.org/10.1182/blood.V108.11.3012.3012

Published: 2006

Journal Articles

A Quality of Life Assessment of Ablative Allogeneic Bone Marrow Transplant (BMT) Recipients One and Twelve Months after Transplant.

Brian Bolwell, MD, Linda McLellan, LISW, Larry Foster, Ph.D, Lisa Rybicki, Ronald M. Sobecks, MD, Brad Pohlman, MD, Steve Andresen, DO, Elizabeth Kuczkowski, Mary Serafin, R.N., Karen Sands, R.N., Jennifer Kosar, R.N., Stacey Brown, Jennifer Bates, Mikkael Sekeres, MD, MS, Jane Dabney, LISW, Erin Welsh, LSW, Matt Kalaycio, MD

Blood (2005) 106 (11): 1322.

https://doi.org/10.1182/blood.V106.11.1322.1322

Published: 2005

Journal Articles

Autologous Stem Cell Transplantation (ABMT) for Recurrent Hodgkin’s Disease from 1990–2005: Factors Contributing to Post-Transplant Relapse.

Brian Bolwell, MD, Brad Pohlman, MD, Matt Kalaycio, MD, Steve Andresen, DO, Elizabeth Kuczkowski, Stacey Brown, Jennifer Bates, Lisa Rybicki, Julie Curtis, R.N., Kimberly Bell, R.N., Ronald M. Sobecks, MD

Blood (2005) 106 (11): 2083.

https://doi.org/10.1182/blood.V106.11.2083.2083

Published: 2005

Journal Articles

Tandem Autologous Stem Cell Transplantation for Patients with Primary Progressive or Rapidly Relapsing Hodgkin’s Disease.

Brian Bolwell, MD, Brad Pohlman, MD, Ronald Sobecks, MD, Steven Andresen, DO, Lisa Rybicki, Stacey Brown, Elizabeth Kuczkowski, Jennifer Bates, Laura Bernhard, R.N., Kelly Cherni, R.N., Janet Baker, R.N., Matt Kalaycio, M.D.

Blood (2005) 106 (11): 5482.

https://doi.org/10.1182/blood.V106.11.5482.5482

Published: 2005

Journal Articles

Very High Hospital Admission Rate after Outpatient Non-Myeloablative Allogeneic Stem Cell Transplant Using Fludarabine and Low Dose TBI.

Brian Bolwell, MD, Lisa Rybicki, Matt Kalaycio, MD, Brad Pohlman, MD, Steven Andresen, DO, Stacey Brown, Elizabeth Kuczkowski, Jennifer Bates, Laura Bernhard, R.N., Kelly Cherni, R.N., Janet Baker, R.N., Ronald Sobecks, MD

Blood (2005) 106 (11): 3667.

https://doi.org/10.1182/blood.V106.11.3667.3667

Published: 2005

Journal Articles

Improved Outcomes with Class I and II DNA-Based HLA Typing for Matched Unrelated Donor (MUD) Allogeneic Bone Marrow Transplant (ABMT) in Hematologic Diseases.

Ronald Sobecks, M.D., Edward J. Ball, PhD, Lisa Rybicki, Elizabeth Kuczkowski, Matt Kalaycio, M.D., Brad Pohlman, M.D., Steven Andresen, D.O., Karen Sands, R.N., Jennifer Kosar, R.N., Mary Serafin, R.N., Jennifer Bates, Christy Lalli, Brian Bolwell, M.D.

Blood (2004) 104 (11): 5181.

https://doi.org/10.1182/blood.V104.11.5181.5181

Published: 2004

Journal Articles

High Dose Therapy with Autologous Blood Stem Cell Transplantation (ASCT) for Follicular Lymphoma: Long-Term Outcome According to Histologic Grade.

Brad Pohlman, M.D., Tony Jin, Kristie Summers, Elizabeth Kuczkowski, Matt Kalaycio, M.D., Ronald Sobecks, M.D., Steven Andresen, D.O., Laura Bernhard, R.N., Kelly Cherni, R.N., Janet Baker, R.N., Jennifer Bates, Brian J. Bolwell, M.D.

Blood (2004) 104 (11): 896.

https://doi.org/10.1182/blood.V104.11.896.896

Published: 2004

Journal Articles

Autologous Transplantation for Diffuse Large B Cell Lymphoma: Pre-Transplant Hypogammaglobulinemia Is a Predictor for Early Toxicities.

Brian J. Bolwell, M.D., Matt Kalaycio, M.D., Ronald Sobecks, M.D., Steven Andresen, D.O., Lisa Rybicki, Elizabeth Kuczkowski, Jennifer Bates, Kristie Summers, Laura Bernhard, Kelly Cherni, Janet Baker, Stacey Brown, Brad Pohlman, M.D.

Blood (2004) 104 (11): 908.

https://doi.org/10.1182/blood.V104.11.908.908

Published: 2004

NARROW

Response to High Dose Cytarabine (HIDAC) As First Salvage for Relapsed Acute Lymphocytic Leukemia in Patients Receiving HIDAC As Initial Therapy

Absolute Lymphocyte Count At Day 28 Independently Predicts Event-Free and Overall Survival in Adults with Newly Diagnosed Acute Lymphocytic Leukemia

Lenalidomide and Rituximab Following Autologous Stem Cell Transplantation for B-Cell Non-Hodgkin Lymphoma Is Associated with Unacceptable Myelotoxicity

Expression of Phosphorylated Signal Transducer and Activator of Transcription 5 (pSTAT5) Is Associated with An Increased Risk of Death In Acute Myeloid Leukemia.

A Phase 1 Trial of Imatinib Mesylate with Daunorubicin and Cytarabine for Patients with C-Kit Positive Relapsed AML.

A Phase 1 Trial of Imatinib Mesylate in Combination with Daunorubicin and Cytarabine for Patients for C-kit Positive Relapsed Acute Myeloid Leukemia (AML).

Comparison of T Cell (CD3+) Chimerism after Myeloablative (MY) and Nonmyeloablative (NM) Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT).

Influence of Killer Immunoglobulin-Like Receptor (KIR) Matching on Achieving T Cell (CD3+) Complete Donor Chimerism (CDC) in Related Donor Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NMHSCT).

A Quality of Life Assessment of Ablative Allogeneic Bone Marrow Transplant (BMT) Recipients One and Twelve Months after Transplant.

Autologous Stem Cell Transplantation (ABMT) for Recurrent Hodgkin’s Disease from 1990–2005: Factors Contributing to Post-Transplant Relapse.

Tandem Autologous Stem Cell Transplantation for Patients with Primary Progressive or Rapidly Relapsing Hodgkin’s Disease.

Very High Hospital Admission Rate after Outpatient Non-Myeloablative Allogeneic Stem Cell Transplant Using Fludarabine and Low Dose TBI.

Improved Outcomes with Class I and II DNA-Based HLA Typing for Matched Unrelated Donor (MUD) Allogeneic Bone Marrow Transplant (ABMT) in Hematologic Diseases.

High Dose Therapy with Autologous Blood Stem Cell Transplantation (ASCT) for Follicular Lymphoma: Long-Term Outcome According to Histologic Grade.

Autologous Transplantation for Diffuse Large B Cell Lymphoma: Pre-Transplant Hypogammaglobulinemia Is a Predictor for Early Toxicities.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only